Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Malfunction of subpectorally implanted cardiac resynchronization therapy defibrillators due to weakened header bond.

Hayat SA, Kojodjojo P, Mason A, Benfield A, Wright I, Whinnett Z, Lim PB, Davies DW, Lefroy D, Peters NS, Kanagaratnam P.

J Cardiovasc Electrophysiol. 2013 Mar;24(3):351-5. doi: 10.1111/j.1540-8167.2012.02421.x. Epub 2012 Nov 6.

PMID:
23131091
2.

Battery longevity in cardiac resynchronization therapy implantable cardioverter defibrillators.

Alam MB, Munir MB, Rattan R, Flanigan S, Adelstein E, Jain S, Saba S.

Europace. 2014 Feb;16(2):246-51. doi: 10.1093/europace/eut301. Epub 2013 Oct 6.

PMID:
24099864
3.

Impact of extending device longevity on the long-term costs of implantable cardioverter-defibrillator therapy: a modelling study with a 15-year time horizon.

Boriani G, Braunschweig F, Deharo JC, Leyva F, Lubinski A, Lazzaro C.

Europace. 2013 Oct;15(10):1453-62. doi: 10.1093/europace/eut133. Epub 2013 May 21.

PMID:
23696624
4.

Longevity of implantable cardioverter-defibrillators for cardiac resynchronization therapy in current clinical practice: an analysis according to influencing factors, device generation, and manufacturer.

Landolina M, Curnis A, Morani G, Vado A, Ammendola E, D'onofrio A, Stabile G, Crosato M, Petracci B, Ceriotti C, Bontempi L, Morosato M, Ballari GP, Gasparini M.

Europace. 2015 Aug;17(8):1251-8. doi: 10.1093/europace/euv109. Epub 2015 May 14.

5.

Sprint Fidelis lead fractures in patients with cardiac resynchronization therapy devices: insight from the Resynchronization/Defibrillation for Ambulatory Heart Failure (RAFT) study.

Parkash R, Thibault B, Sterns L, Sapp J, Krahn A, Talajic M, Luce M, Yetisir E, Theoret-Patrick P, Wells G, Tang A.

Circulation. 2012 Dec 18;126(25):2928-34. doi: 10.1161/CIRCULATIONAHA.112.132100. Epub 2012 Nov 16.

6.

Implantation feasibility, procedure-related adverse events and lead performance during 1-year follow-up in patients undergoing triple-site cardiac resynchronization therapy: a substudy of TRUST CRT randomized trial.

Lenarczyk R, Kowalski O, Sredniawa B, Pruszkowska-Skrzep P, Mazurek M, Jędrzejczyk-Patej E, Woźniak A, Pluta S, Głowacki J, Kalarus Z.

J Cardiovasc Electrophysiol. 2012 Nov;23(11):1228-36. doi: 10.1111/j.1540-8167.2012.02375.x. Epub 2012 May 31.

PMID:
22651239
7.

Importance of Implantable Cardioverter-Defibrillator Back-Up in Cardiac Resynchronization Therapy Recipients: A Systematic Review and Meta-Analysis.

Barra S, Providência R, Tang A, Heck P, Virdee M, Agarwal S.

J Am Heart Assoc. 2015 Nov 6;4(11). pii: e002539. doi: 10.1161/JAHA.115.002539. Review.

8.

Lower incidence of inappropriate shock therapy in patients with combined cardiac resynchronisation therapy defibrillators (CRT-D) compared with patients with non-CRT defibrillators (ICDs).

Chen Z, Kotecha T, Crichton S, Shetty A, Sohal M, Arujuna A, Kirubakaran S, Bostock J, Cooklin M, O'Neill M, Wright M, Gill JS, Rinaldi CA.

Int J Clin Pract. 2013 Aug;67(8):733-9. doi: 10.1111/ijcp.12033.

PMID:
23869676
9.

Ampere Hour as a Predictor of Cardiac Resynchronization Defibrillator Pulse Generator Battery Longevity: A Multicenter Study.

Ellis CR, Dickerman DI, Orton JM, Hassan S, Good ED, Okabe T, Andriulli JA, Quan KJ, Greenspon AJ.

Pacing Clin Electrophysiol. 2016 Jul;39(7):658-68. doi: 10.1111/pace.12831. Epub 2016 Mar 11. Review.

PMID:
26875541
10.

Clinical effectiveness of cardiac resynchronization and implantable cardioverter-defibrillator therapy in men and women with heart failure: findings from IMPROVE HF.

Wilcox JE, Fonarow GC, Zhang Y, Albert NM, Curtis AB, Gheorghiade M, Heywood JT, Mehra MR, O'Connor CM, Reynolds D, Walsh MN, Yancy CW.

Circ Heart Fail. 2014 Jan;7(1):146-53. doi: 10.1161/CIRCHEARTFAILURE.113.000789. Epub 2013 Oct 31.

11.

Lead extraction: The road to successful cardiac resynchronization therapy.

Maciąg A, Syska P, Sterliński M, Przybylski A, Sitkowska E, Oręziak A, Bilińska M, Kuśmierczyk M, Szwed H.

Cardiol J. 2015;22(2):188-93. doi: 10.5603/CJ.a2014.0064. Epub 2014 Oct 9.

PMID:
25299498
12.

Incidence, predictors, and procedural results of upgrade to resynchronization therapy: the RAFT upgrade substudy.

Essebag V, Joza J, Birnie DH, Sapp JL, Sterns LD, Philippon F, Yee R, Crystal E, Kus T, Rinne C, Healey JS, Sami M, Thibault B, Exner DV, Coutu B, Simpson CS, Wulffhart Z, Yetisir E, Wells G, Tang AS.

Circ Arrhythm Electrophysiol. 2015 Feb;8(1):152-8. doi: 10.1161/CIRCEP.114.001997. Epub 2014 Nov 23.

13.

Relation of QRS Duration to Clinical Benefit of Cardiac Resynchronization Therapy in Mild Heart Failure Patients Without Left Bundle Branch Block: The Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy Substudy.

Biton Y, Kutyifa V, Cygankiewicz I, Goldenberg I, Klein H, McNitt S, Polonsky B, Ruwald AC, Ruwald MH, Moss AJ, Zareba W.

Circ Heart Fail. 2016 Feb;9(2):e002667. doi: 10.1161/CIRCHEARTFAILURE.115.002667.

14.

An analysis of implantable cardiac device reliability. The case for improved postmarketing risk assessment and surveillance.

Laskey W, Awad K, Lum J, Skodacek K, Zimmerman B, Selzman K, Zuckerman B.

Am J Ther. 2012 Jul;19(4):248-54. doi: 10.1097/MJT.0b013e3182512ca5.

PMID:
22668602
15.

PR interval identifies clinical response in patients with non-left bundle branch block: a Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy substudy.

Kutyifa V, Stockburger M, Daubert JP, Holmqvist F, Olshansky B, Schuger C, Klein H, Goldenberg I, Brenyo A, McNitt S, Merkely B, Zareba W, Moss AJ.

Circ Arrhythm Electrophysiol. 2014 Aug;7(4):645-51. doi: 10.1161/CIRCEP.113.001299. Epub 2014 Jun 24.

16.

Cardiac resynchronization therapy reduces T-wave alternans in patients with heart failure.

Hua W, Chen K, Zhou X, Dai Y, Chen R, Wang J, Ding L, Liu Z, Feng T, Yu J, Cheng J, Liu C, Zhang S.

Europace. 2015 Feb;17(2):281-8. doi: 10.1093/europace/euu258. Epub 2014 Nov 14.

PMID:
25398405
17.

Association between left ventricular ejection fraction post-cardiac resynchronization treatment and subsequent implantable cardioverter defibrillator therapy for sustained ventricular tachyarrhythmias.

Manfredi JA, Al-Khatib SM, Shaw LK, Thomas L, Fogel RI, Padanilam B, Rardon D, Vatthyam R, Gemma LW, Golden K, Prystowsky EN.

Circ Arrhythm Electrophysiol. 2013 Apr;6(2):257-64. doi: 10.1161/CIRCEP.112.000214. Epub 2013 Feb 26.

18.

The efficacy and safety of cardiac resynchronization therapy combined with implantable cardioverter defibrillator for heart failure: a meta-analysis of 5674 patients.

Chen S, Ling Z, Kiuchi MG, Yin Y, Krucoff MW.

Europace. 2013 Jul;15(7):992-1001. doi: 10.1093/europace/eus419. Epub 2013 Feb 17. Review.

PMID:
23419662
19.

Temporal Influence of Heart Failure Hospitalizations Prior to Implantable Cardioverter Defibrillator or Cardiac Resynchronization Therapy With Defibrillator on Subsequent Outcome in Mild Heart Failure Patients (from MADIT-CRT).

Lee AY, Moss AJ, Ruwald MH, Kutyifa V, McNitt S, Polonsky B, Zareba W, Ruwald AC.

Am J Cardiol. 2015 May 15;115(10):1423-7. doi: 10.1016/j.amjcard.2015.02.029. Epub 2015 Feb 18.

PMID:
25817576
20.

Impact of carvedilol and metoprolol on inappropriate implantable cardioverter-defibrillator therapy: the MADIT-CRT trial (Multicenter Automatic Defibrillator Implantation With Cardiac Resynchronization Therapy).

Ruwald MH, Abu-Zeitone A, Jons C, Ruwald AC, McNitt S, Kutyifa V, Zareba W, Moss AJ.

J Am Coll Cardiol. 2013 Oct 8;62(15):1343-50. doi: 10.1016/j.jacc.2013.03.087. Epub 2013 Jun 13.

Supplemental Content

Support Center